NKE
New CFO, same marathon
Nike just named David Denton — yes, the former CFO at Pfizer — as its new finance chief and kept its outlook intact. That’s a classic “new quarterback, same game plan” move, which can calm the room, but it doesn’t magically turn a rebuild into a sprint.
Why investors care
A CFO switch matters because Nike’s turnaround is really a numbers story: inventory, margins, demand, and whether the brand can get back to flexing in the right places. Reaffirming guidance helps, sure. But the market usually wants something more delicious than corporate reassurance — it wants evidence.
The waiting game
The article’s key point is basically this: the turnaround may still be several quarters from showing up in a way you can actually feel in the stock. So if you were hoping for a clean “problem solved” moment, Nike is still in the messy middle, where the story is less Rocky montage and more rehab schedule.
Big picture
For now, Nike has swapped in a fresh finance boss, but the real test is whether the next few quarters bring better proof that the comeback is actually sticking.